FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 15:39:53 2024-06-26 EDT | ||
| 2.77 EUR | 0.00% |
|
| Current month | -10.93% | ||
| 1 month | -10.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 2.77 | 0.00% |
| 24-06-25 | 2.77 | +1.84% |
| 24-06-24 | 2.72 | -3.55% |
| 24-06-21 | 2.82 | +0.36% |
| 24-06-20 | 2.81 | -2.09% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:39 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SV4ARC |
| ISIN | DE000SV4ARC4 |
| Date issued | 2023-04-14 |
| Strike | 326.4 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.37 € |
|---|---|
| Lowest since issue | 2.47 € |
| Spread | 0.01 € |
| Spread % | 0.36% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
